Faeth Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Faeth Therapeutics, Inc. carries a market capitalization of 32.86M, placing it among publicly traded companies globally. Its enterprise value stands at -161.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 32.86M |
| Enterprise Value | -161.65M |
Share Statistics
Faeth Therapeutics, Inc. currently has 1.34M shares outstanding.
| Shares Outstanding | 1.34M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.09 |
| P/TBV Ratio | -0.29 |
| P/FCF Ratio | -1.67 |
| P/OCF Ratio | -1.66 |
Financial Position
Faeth Therapeutics, Inc. maintains a current ratio of 14.39, meaning it holds 14.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -0.76, indicating conservative leverage, while an interest coverage ratio of -9,763.47 demonstrates limited ability to service its debt obligations.
| Current Ratio | 14.39 |
| Quick Ratio | 14.29 |
| Debt / Equity | -0.76 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -9,763.47 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -151.41 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Faeth Therapeutics, Inc.'s stock has gained approximately 167.65027% over the past 52 weeks. The 50-day moving average sits at 20.99, while the 200-day moving average is 17.09.
| Beta (5Y) | N/A |
| 52-Week Price Change | 167.65027% |
| 50-Day Moving Average | 20.99 |
| 200-Day Moving Average | 17.09 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -185.51M, while operating income came in at -185.64M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -185.64M |
| Pretax Income | -184.46M |
| Net Income | -184.46M |
| EBITDA | -185.51M |
| EBIT | -185.64M |
| Earnings Per Share (EPS) | -144.97 |
Balance Sheet
Faeth Therapeutics, Inc. holds 202.79M in cash and equivalents against 1.04M in total debt, resulting in a net debt position of -152.32M. Total book value stands at -453.37M, with working capital of 190.04M providing operational flexibility.
| Cash & Cash Equivalents | 202.79M |
| Total Debt | 1.04M |
| Net Debt | -152.32M |
| Equity (Book Value) | -453.37M |
| Book Value Per Share | -356.31 |
| Working Capital | 190.04M |
Cash Flow
Faeth Therapeutics, Inc. produced -24.09M in operating cash flow over the past twelve months. After subtracting -22,000.00 in capital expenditures, free cash flow totaled -24.11M - equivalent to -18.95 per share.
| Operating Cash Flow | -24.09M |
| Capital Expenditures | -22,000.00 |
| Free Cash Flow | -24.11M |
| FCF Per Share | -18.95 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -462.26 |
| FCF Yield | -60.02 |
Scores
Faeth Therapeutics, Inc. posts an Altman Z-Score of -4.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.89 |